Anthropic Researcher Quits Over Superintelligence Warning as IPO Talk Swirls

An Anthropic researcher resigned this week and used the exit to accuse the company of racing toward self-improving superintelligence, writing on X that the lab is "gambling with our lives." The post landed harder than a typical departing-employee gripe because Anthropic's own alignment lead co-signed it, choosing to amplify the criticism instead of walking it back. For a company that has built its public identity around safety, that is not a stray comment — it is a split showing at the top of the org chart.

The substance of the warning is familiar from years of AI doomer writing: systems that improve themselves without meaningful human oversight, and labs competing in a race where no one wants to slow down first. What is new is the source. This is not an outside critic or an academic with no stake; it is someone who worked inside one of the two or three most capable labs on earth, saying the danger is live rather than theoretical. The alignment lead's endorsement removes the easiest defense Anthropic had, which was to treat the resignation as one employee's personal view.

Timing is doing a lot of work here. Anthropic is reportedly preparing for an initial public offering, a process that forces a company to put numbers, growth projections, and risk factors in front of public-market investors. Safety-first positioning is a recruiting and regulatory asset in private markets. In an S-1, it becomes something else: a set of claims that lawyers, bankers, and eventually shareholders will hold the company to. A public resignation that accuses the firm of gambling with human lives is exactly the kind of item that complicates that story.

The internal contradiction is not unique to Anthropic. Every major lab says some version of the same thing — that frontier models carry serious risk, that safety work matters, and that the race must continue because rivals will not stop. Those three claims sit in tension, and the tension gets harder to manage as valuations climb and timelines compress. When a company's own alignment staff sign onto the harshest version of the critique, the gap between the marketing and the internal belief becomes visible to everyone, including regulators and prospective investors.

What happens next depends on how Anthropic responds. A statement that acknowledges the concern and points to concrete safety commitments would keep the story contained; silence or a dismissive reply would let it grow, especially if other employees follow the resignee's lead. Watch whether the co-signing alignment lead stays in his role, whether the IPO process surfaces new risk language about superintelligence, and whether rival labs face the same question from their own safety staff. The uncomfortable possibility is that this is not an Anthropic problem but an industry one, and the first company to say so out loud may be the one that looks most honest.